Persons with neurofibromatosis type 1 (NF1) have a predisposition for premature and severe arterial stenosis. Mutations in the NF1 gene result in decreased expression of neurofibromin, a negative regulator of p21Ras, and increases Ras signaling. Heterozygous Nf1 (Nf1+/−) mice develop a marked arterial stenosis characterized by proliferating smooth muscle cells (SMCs) and a predominance of infiltrating macrophages, which closely resembles arterial lesions from NF1 patients. Interestingly, lineage-restricted inactivation of a single Nf1 allele in monocytes/macrophages is sufficient to recapitulate the phenotype observed in Nf1+/− mice and to mobilize proinflammatory CCR2+ monocytes into the peripheral blood. Therefore, we hypothesized that CCR2 receptor activation by its primary ligand monocyte chemotactic protein-1 (MCP-1) is critical for monocyte infiltration into the arterial wall and neointima formation in Nf1+/− mice. MCP-1 induces a dose-responsive increase in Nf1+/− macrophage migration and proliferation that corresponds with activation of multiple Ras kinases. In addition, Nf1+/− SMCs, which express CCR2, demonstrate an enhanced proliferative response to MCP-1 when compared with WT SMCs. To interrogate the role of CCR2 activation on Nf1+/− neointima formation, we induced neointima formation by carotid artery ligation in Nf1+/− and WT mice with genetic deletion of either MCP1 or CCR2. Loss of MCP-1 or CCR2 expression effectively inhibited Nf1+/− neointima formation and reduced macrophage content in the arterial wall. Finally, administration of a CCR2 antagonist significantly reduced Nf1+/− neointima formation. These studies identify MCP-1 as a potent chemokine for Nf1+/− monocytes/macrophages and CCR2 as a viable therapeutic target for NF1 arterial stenosis.
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder affecting 1 in 3000 persons and is the result of inactivating mutations in the NF1 tumor suppressor gene. Neurofibromin, the protein product of NF1, functions as a GTPase activating protein for p21ras (Ras) and accelerates the slow, intrinsic hydrolysis of active Ras-GTP to its inactive diphosphate conformation (1). Inherited mutations of NF1 affect a single gene copy and result in disease with complete penetrance and a broad range of clinical features.
Cardiovascular disease represents a common, yet understudied, manifestation of NF1 that contributes to the early mortality observed in this patient population (2). NF1 vasculopathy primarily affects the arterial network with a strong predilection for the renal artery and proximal branches of the carotid artery. The exact frequency of vasculopathy in NF1 patients is unknown; however, multiple case series and large patient cohorts suggest the prevalence of arterial disease approaches 10% (3–7). The insidious and progressive clinical presentation of these lesions in early adulthood likely places the true incidence much higher. In fact, histologic evidence of cardiovascular disease was identified in nearly 50% of young adults with NF1 in one case series (8), whereas a comprehensive review of 3253 death certificates revealed a diagnosis of vasculopathy was listed 7.2 times more frequently than expected among NF1 patients less than 30 years of age at the time of death (4).
Arterial lesions associated with NF1 are characterized by smooth muscle cell (SMC) hyperplasia, leukocyte infiltration and arterial remodeling leading to vasoocclusion and tissue ischemia (2,9–11). Previously, we developed a mouse model of NF1 arterial stenosis using Nf1 heterozygous (Nf1+/−) mice that completely recapitulates the human phenotype (12). Although neointima formation is the result of complex interactions between vascular wall cells and circulating leukocytes, we showed that loss of a single Nf1 allele in bone marrow cells is both necessary and sufficient to induce arterial stenosis (13). These results were somewhat surprising, because neurofibromin-deficient SMC have increased proliferation and migration in response to multiple growth factors and Nf1+/− macrophages (13,14). Neurofibromin-deficient macrophages are the dominant hematopoietic cell within the neointima of Nf1+/− mice and likely secrete cytokines and chemokines that stimulate SMC proliferation and migration (13,15). Thus, it is plausible that loss of neurofibromin in bone marrow and circulating hematopoietic cells, particularly monocytes and macrophages, may predispose NF1 patients to develop exaggerated responses to acute and chronic inflammation or insult. Emerging evidence in NF1 patients is supportive of this hypothesis. Asymptomatic NF1 patients have increased circulating proinflammatory cytokines and monocytes (CD14+CD16+) in the peripheral blood compared with controls (13). Similar to NF1 patients, Nf1+/− mice have increased circulating Ly6ChiCCR2+ monocytes, which are the murine correlate of human proinflammatory monocytes (15,16). Murine Ly6ChiCCR2+ leukocytes are primitive bone-marrow-derived monocytes that are actively recruited to sites of inflammation and differentiate into macrophages and inflammatory dendritic cells (17,18). In support of our hypothesis that neurofibromin regulates inflammatory cascades in circulating leukocytes, we recently showed that loss of a single Nf1 gene copy in myeloid cells was sufficient to mobilize Ly6ChiCCR2+ monocytes and induce arterial stenosis following carotid artery ligation (15). Interestingly, genetic deletion of both Nf1 gene copies in myeloid cells alone resulted in a 4-fold increase in circulating Ly6ChiCCR2+ monocytes and nearly complete arterial occlusion following carotid ligation (15).
Based on these observations, we generated compound mutant mice to test the hypothesis that CCR2 activation is critical for Nf1+/− macrophage recruitment to sites of vascular injury and necessary for Nf1+/− neointima formation. Further, we sought to understand how CCR2 activation by its primary ligand, monocyte chemotactic protein-1 (MCP-1/CCL2), mediates neurofibromin-deficient macrophage function and SMC proliferation. Finally, we use our murine model system to test the efficacy of a potent and specific inhibitor of the CCR2 receptor as a potential therapeutic intervention in the treatment of NF1 arterial stenosis.
MCP-1 is a potent chemokine for Nf1+/− macrophages and SMC
MCP-1 is a monomeric polypeptide anchored to the endothelial monolayer of blood vessels and secreted by SMC and circulating leukocytes (19,20). The chemotactic properties of MCP-1 are primarily mediated through its activation of the CCR2 receptor (19,21–23). Importantly, the expression of CCR2 in the cardiovascular system is restricted to endothelial cells (ECs), SMC and monocytes/macrophages and is not a mediator of granulocyte chemotaxis (24–26). Therefore, we derived Nf1+/− and WT macrophages from Nf1+/− and WT mice to assess their functional response to MCP-1 stimulation. At baseline, Nf1+/− macrophages demonstrate a 2-fold increase in migration, but do not exhibit enhanced proliferation. In response to MCP-1 incubation, Nf1+/− macrophages exhibited a dose-dependent increase in chemotaxis and proliferation when compared with WT macrophages (Fig. 1A and B). Although MCP-1 also increased WT macrophage migration and proliferation in a dose-dependent manner, MCP-1 stimulated a 2- to 3-fold increase in Nf1+/− macrophage migration and proliferation when compared with WT macrophages at the same concentration of MCP-1. Interestingly, analysis of culture media from growth-arrested Nf1+/− and WT macrophages revealed an increased concentration of MCP-1 in the media of cultured Nf1+/− macrophages when compared with WT macrophage media (Fig. 1C). Cell counts of growth-arrested macrophages did not differ between genotypes (data not shown). Next, we analyzed neurofibromin-regulated Ras kinase activity to determine which pathway may be preferentially activated in in Nf1+/− macrophages in response to MCP-1 (Fig. 1D). While phosphorylation of both Erk and Akt was demonstrated in Nf1+/− macrophages incubated with MCP-1, the increase in p-Erk/Erk ratio did not differ between Nf1+/− and WT macrophages incubated with MCP-1 and likely represents an increase in Erk activity that is independent of neurofibromin expression. Akt phosphorylation, on the other hand, was dramatically higher in Nf1+/− macrophages stimulated with MCP-1 when compared with WT macrophages stimulated with MCP-1. Thus, Nf1+/− macrophages exhibit an exaggerated response to MCP-1 stimulation that corresponds with preferential activation of the PI3-K–Akt pathway.
Infiltrating macrophages secrete growth factors and cytokines to induce SMC proliferation and inward remodeling, which are hallmarks of arterial stenosis. Although genetic deletion of Nf1 in SMC is not required for Nf1+/− neointima formation, Nf1+/− SMCs demonstrate enhanced proliferation in response to multiple growth factors and co-incubation with Nf1+/− and WT macrophages (14,15,27). Based on the observation that Nf1+/− macrophages exhibit increased production of MCP-1 and that SMC express CCR2, we isolated SMC from WT, Nf1+/− and Nf1+/−;CCR2−/− mice to assess their proliferative response to MCP-1. Similar to previous published reports, WT SMC showed a modest proliferative response to MCP-1 (28–31) (Fig. 2A). While Nf1+/− SMCs are more proliferative at baseline, Nf1+/− SMC exhibited a nearly 2-fold increase in proliferation in response to MCP-1 stimulation when compared with untreated Nf1+/− SMC. MCP-1 expression in cultured Nf1+/− SMC and secretion into growth media was similar to WT SMC (data not shown). Genetic deletion of CCR2 in Nf1+/− SMC completely abolished the proliferative response mediated by MCP-1 and demonstrates that MCP-1 is primarily activating CCR2 on Nf1+/− SMC (Fig. 2A). Examination of Ras-dependent kinase activity revealed a profound increase in Erk signaling in Nf1+/− SMC stimulated with MCP-1 when compared with unstimulated Nf1+/− SMC (Fig. 2B). MCP-1 did not alter Akt activity in Nf1+/− SMC (data not shown). Based on the substantial increase in Erk activity in response to MCP-1, we incubated Nf1+/− and WT SMC with MCP-1 (10 ng/ml) in the presence or absence of PD0325901, a potent inhibitor of Mek–Erk signaling. At low nanomolar concentrations of PD0325901, MCP-1 failed to evoke a proliferative response in Nf1+/− SMC (Fig. 2C). Not surprisingly, blockade of Erk signaling also reduced WT SMC proliferation and strengthens the argument that Erk activation is critical for MCP-1 elicited SMC proliferation. Collectively, these data suggest that Nf1+/− SMC exhibit enhanced proliferation in response to MCP-1 via Erk activation.
Genetic deletion of MCP-1 or CCR2 abrogates Nf1+/− neointima formation
Based on our observations that MCP-1 is a potent stimulus for Nf1+/− macrophage and SMC, we sought to interrogate the role of MCP-1/CCR2 signaling in the pathogenesis Nf1+/− arterial stenosis. Nf1+/− mice were intercrossed with MCP1−/− mice to generate compound mutant Nf1+/−;MCP1−/− mice. WT, MCP1−/−, Nf1+/− and Nf1+/−; MCP1−/− mice underwent surgical ligation of the right common carotid artery to induce neointima formation. In response to arterial injury, WT mice developed a modest neointima, whereas Nf1+/− mice developed a robust neointimal layer after arterial injury (Fig. 3). Genetic deletion of MCP-1 completely inhibited neointima formation in Nf1+/− mice. Morphometric analysis of serial cross sections revealed a 70% reduction in neointima area (Fig. 3B) and a 55% reduction in intima/media (I/M) ratio (Fig. 3C). Corresponding with the reduced neointima in Nf1+/− mice lacking MCP-1 expression, Mac-3+ macrophage staining in the neointimas of Nf1+/−; MCP1−/− mice were significantly reduced when compared with Nf1+/− neointimas (10.4 ± 3.0% versus 17.3 ± 3.4% of total cell number, P = 0.1; Fig. 3D).
Although MCP-1 primarily binds to CCR2, recent evidence suggests that MCP-1 has non-CCR2-mediated effects in SMC including binding of the CCR4 receptor (32,33). Therefore, we intercrossed Nf1+/− and CCR2−/− mice to examine the role of CCR2 activation on Nf1+/− neointima formation and macrophage infiltration into the vascular wall. The common carotid arteries of WT, CCR2−/−, Nf1+/− and Nf1+/−; CCR2−/− mice were ligated and analyzed for neointima formation after a 28-day recovery period. Similar to our previous experiment, Nf1+/− mice form a large neointima when compared with WT mice. Homozygous deletion of CCR2 in Nf1+/− mice completely abrogated neointima formation and quantitative analysis of arterial cross sections demonstrated that arterial remodeling and neointima size were similar to WT arteries (Fig. 4A–C). Consistent with these observations, Mac-3+ macrophage infiltration into the neointima was reduced in Nf1+/−;CCR2−/− mice when compared with Nf1+/− mice (12.2 ± 2.9% versus 21.53 ± 3.5% of total cell number, P < 0.05; Fig. 4D). Thus, MCP-1 and CCR2 expression are critical for neointima formation in Nf1+/− mice.
Pharmacologic inhibition of CCR2 inhibits Nf1+/− neointima formation
Pharmacologic inhibition of CCR2 could provide an attractive therapeutic target for NF1 patients with evidence of vasculopathy. Therefore, we utilized a specific CCR2 antagonist (INCB3284) for preclinical testing in our murine model system of NF1 arterial stenosis (34). Nf1+/− and WT mice were administered INCB3284 or vehicle via intraperitoneal injection immediately after arterial injury and once daily for 10 days as rescue therapy. This regimen was selected based on published pharmacokinetics for INCB3284 and specific targeting of macrophages during the early phase of arterial remodeling (34). In response to carotid artery ligation, vehicle-treated Nf1+/− mice developed significant intimal hyperplasia, whereas WT mice developed a more modest neointima, which was grossly and quantitatively similar to our previous observations (Fig. 5A–C). Daily administration of INCB 3284 as a rescue therapy significantly reduced neointima formation in Nf1+/− mice when compared with vehicle-treated Nf1+/− mice (Fig. 5B and C). While there was a trend toward reduction of neointima area and I/M ratio in WT mice treated with INCB 3284 when compared with WT mice receiving PBS treatment, statistical significance was not achieved (P = 0.11 and 0.5, respectively). Mac-3+ macrophage content was also reduced in Nf1+/− mice treated with INCB 3284 when compared with Nf1+/− mice receiving PBS treatment (16.3 ± 3.2% versus 24.12 ± 3.1% of total cell number, P < 0.05; Fig. 5D). Weight gain was similar between INCB 3284 and vehicle treatment groups, and no toxicities were observed on autopsy and inspection of visceral organs. These are the first data to suggest that a competitive CCR2 antagonist may be a viable therapeutic intervention for NF1 patients with evidence of cardiovascular disease.
To date, therapeutic interventions for NF1 patients with cardiovascular disease have been limited, and tailored therapies directed at neurofibromin deficiency or its downstream targets are non-existent. Multiple extracellular signaling inputs converge on canonical Ras to maintain normal cell turnover, which limits the long-term use of Ras kinase inhibitors in patients with NF1 cardiovascular disease. Thus, a complete understanding of the pathogenesis of arterial disease in NF1 patients is imperative to inform novel therapeutic approaches leading to disease-specific clinical trials. Along this line of reasoning, emerging evidence suggests that NF1 patients experience chronic inflammation including increased cytokine production and frequency of circulating proinflammatory CD14+CD16+ monocytes in their peripheral blood (13). These findings are supported by our recent observation that Nf1+/− mice have increased circulating Ly6Chi monocytes, which closely resemble human proinflammatory intermediate monocytes (16). Increased cell surface expression of CCR2 is characteristic of Ly6Chi monocytes and enables these primitive myeloid cells to emigrate from the bone marrow and home to sites of inflammation where they differentiate into macrophages and secrete growth factors, reactive oxygen species and cytokines (35). Neurofibromin appears to play a central role in their derivation and mobilization from the bone marrow. Similar to Nf1+/− mice, mice harboring a lineage-restricted deletion of a single Nf1 gene copy in myeloid cells have increased Ly6ChiCCR2+ monocytes in the peripheral blood (15). Interestingly, genetic deletion of both Nf1 gene copies resulted in a 4-fold increase in circulating Ly6ChiCCR2+ monocyte frequency, which strongly suggests that neurofibromin directly regulates monocyte mobilization and inflammation via a cell autonomous and gene-dosage-dependent mechanism (15).
Not surprisingly, monocytes and macrophages appear to play a central role in the pathogenesis of NF1-related arterial stenosis. Experimental ligation of the common carotid artery in mice harboring a myeloid-specific deletion of Nf1 results in a robust neointima that is identical to Nf1+/− mice and NF1 patients. Deletion of both Nf1 alleles in myeloid cells resulted in a near-total occlusion of the carotid artery after injury. Thus, neointima formation in Nf1-mutant mice is directly regulated by neurofibromin expression in myeloid cells via a gene-dosage-dependent mechanism. Based on the observation that neointima formation and CCR2+, inflammatory monocyte frequency is directly regulated by myeloid cell-specific mutations in the Nf1 gene, we utilized MCP-1 and CCR2 knockout mice to specifically interrogate the role of neurofibromin in regulating CCR2-dependent monocyte mobilization and homing during cardiovascular remodeling. Here we show that loss of MCP-1 or CCR2 expression prevents macrophage infiltration into the arterial wall and abolishes neointima formation in Nf1+/− mice. The recruitment of bone marrow monocytes appears to be strongly linked to the presence and activation of CCR2. CCR2-deficient mice have a dramatic reduction in mature monocyte frequency in the peripheral blood, whereas the bone marrow appears to be enriched with primitive and precursor myeloid cells indicating that CCR2 participates in the mobilization of monocytes from the bone marrow (25,36,37). Monocyte differentiation in CCR2−/− mice remains intact; however, mature monocytes fail to accumulate in the spleen and respond to inflammatory stimuli (36). Surprisingly, CCR2 deletion failed to reduce neointima formation in our experimental model system. The demonstrated reduction in neointima formation in CCR2-deficient mice has largely been demonstrated in compound mutant mice (i.e. CCR2−/−;ApoE−/−) and may rely on a hyperlipidemic background to mediate its effects (38,39). Further, C57Bl/6 mice are highly resistant to arterial remodeling in multiple animal models, which is consistent with our experimental results and previous reports (12,13,15,27,40).
Although MCP-1 is the principal ligand for CCR2, other monocyte chemotactic proteins have affinity for CCR2 and have a role in monocyte function, SMC proliferation and arterial remodeling (25,41,42). Thus, complimentary studies in Nf1+/− mice lacking MCP-1 expression were critical to link the increased sensitivity of neurofibromin-deficient monocytes/macrophages to MCP-1 and the mobilization of CCR2+ proinflammatory monocytes in Nf1-mutant mice. The lack of neointima formation in Nf1+/−;MCP1−/− mice mirrors our findings in CCR2-deficient Nf1+/− mice and provides strong genetic evidence that this signaling axis is necessary for Nf1+/− neointima formation. The underlying mechanisms of this interaction remain unclear; however, we show that MCP-1 preferentially activates Erk signaling in Nf1+/− SMC and multiple Ras-dependent kinases in Nf1+/− monocytes, including Akt. Interestingly, Erk and Akt, the primary downstream targets of Ras, activate several transcription factors including SP-1, c-Jun and AP-1, which control the expression of MCP-1 and other cytokines (43–46). In turn, expression of chemokines such as MCP-1 largely controls leukocyte and SMC function via RTK-mediated Ras activation. This may contribute to a positive feedback loop where cytokines can propagate their own production, which may be amplified in the setting of Ras deregulation (47–49). Our observation that neurofibromin-deficient macrophages have increased production and secretion of MCP-1, which may potentiate their own function, is congruent with this line of investigation. For example, mTOR signaling is proximally regulated by neurofibromin and loss of neurofibromin increases Akt activity in response to MCP-1 in murine monocytes. Recent studies in human and murine monocytes have revealed that MCP-1 production is directly regulated by mTOR activation and that inhibition of mTOR signaling results in decreased MCP-1 expression and secretion via an NF-κB-dependent mechanism. Interestingly genetic deletion of tuberous sclerosis complex 2 amplifies mTOR signaling and also increases MCP-1 expression, which suggests that this pathway directly regulates MCP-1 production. Therefore, it is plausible that decreased expression of neurofibromin may enhance downstream signaling networks that increase MCP-1 expression to provide a greater local concentration of MCP-1 to activate CCR2 on circulating monocytes/macrophages and vascular wall cells. While long-term use of an mTOR inhibitor for the prevention or treatment of NF1 vasculopathy is unlikely, interrogation of this pathway may provide substantial mechanistic insights into the regulation of monocyte-specific chemokines and their function in the setting of neurofibromin deficiency. Ongoing studies in our laboratory are focused on understanding how Ras signaling controls the transcription and/or activity of MCP-1.
Targeted therapies directed against either MCP-1 have yielded promising results in preclinical animal models, but have largely proven to lack efficacy in human clinical trials (50–55). Bindarit, an indazolic derivative that binds to the promoter of the MCP-1 gene and limits MCP-1 expression, inhibits human and murine SMC proliferation and de-differentiation as well as neointima formation in several animal models (28,55,56). However, the use of a monoclonal antibody directed against MCP-1 in persons with rheumatoid arthritis did not improve clinical symptoms and demonstrated a dose-responsive increase in serum MCP-1 concentrations, which suggests that clearance of the antibody complex is limited (57). Antibodies directed against MCP-1 in the treatment of cardiovascular disease have not been proposed, though bindarit is presently under investigation for the treatment of diabetic nephropathy. MCP-1 may prove to be a difficult target for the treatment of cardiovascular disease because it is expressed and secreted by multiple cell types, including EC, SMC, leukocytes and perivascular adipocytes, and demonstrates affinity for other receptors including CCR4 (32,33). Further, MCP-1 secretion provides important feedback between perivascular cells (i.e. adipocytes) and remote tissues, including skeletal muscle and hepatocytes (58,59), which makes sequestering MCP-1 activity clinically difficult.
Local inhibition of CCR2, on the other hand, is an attractive therapeutic target for the treatment of NF1 vasculopathy because its expression and ligand-binding affinity is relatively limited. CCR2 antagonists have been studied in multiple clinical trials for the treatment of cardiovascular disease, autoimmunity, chronic inflammation, diabetes and malignancy (60–62). In particular, CCR2 antagonism may prove efficacious in the treatment of multiple manifestations of NF1, because acceleration of Ras activity in myeloid progenitor cells leads to dysfunctional differentiation and increased sensitivity to cytokines and growth factors (1,63–65). Our genetic and pharmacologic data support our hypothesis that MCP-1/CCR2 activation is highly regulated by neurofibromin and may represent a viable therapeutic target for NF1 patients with cardiovascular disease. Further studies directed at understanding how neurofibromin and/or Ras activation control the expression of MCP-1 and facilitate the mobilization of CCR2+ monocytes from the bone marrow are critical for future translational work and human studies of NF1 vasculopathy.
Materials and Methods
Protocols were approved by Laboratory Animal Services at Augusta University and Indiana University. Nf1+/– mice were obtained from Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA) and backcrossed 13 generations into the C57BL/6J strain. MCP-1 (4434) and CCR2 (4999) knockout mice were purchased from The Jackson Laboratory and maintained on C57BL/6 strain. Nf1+/– mice were intercrossed with MCP1 and CCR2 knockout mice to produce Nf1+/–;MCP1−/− and Nf1+/−;CCR2−/− mice. Male mice (12–15 weeks of age) were used for experiments to limit the confounding effects of circulating hormones.
Carotid artery ligation
Carotid artery injury was induced by ligation of the right common carotid artery as described (15). Briefly, mice were anesthetized by inhalation of an isoflurane (2%)/oxygen (98%) mixture. Under a dissecting scope, the right carotid artery was exposed through a midline neck incision and ligated proximal to the bifurcation using a 6–0 silk suture. The contralateral carotid artery was sham ligated as a control. Mice were administered 15 μg of buprenorphine (ip) following the procedure and recovered for 28 days. In some experiments, Nf1+/− and WT mice were administered 15 mg/kg INCB3284 (Caymen Chemical, IC50 3.7 nM and t½ 15 h) or vehicle via IP injection immediately after arterial injury and continued once daily for 10 days.
Van Gieson-stained arterial cross sections 400, 800 and 1200 μm proximal to the ligation were analyzed for neointima formation using ImageJ (NIH, Bethesda, MD). Lumen area, area inside the internal elastic lamina (IEL), and area inside the external elastic lamina (EEL) were measured for each cross section. To account for potential thrombus formation, arteries containing significant thrombus (>50% lumen occlusion) at 400 μm proximal to the ligation were excluded from analysis. The number of excluded arteries was not different between experimental groups. Representative photomicrographs for each figure are taken from arterial cross sections between 600 and 1200 μm proximal to the bifurcation. Intima area was calculated by subtracting the lumen area from the IEL area, and the media area was calculated by subtracting the IEL area from the EEL area. I/M ratio was calculated as intima area divided by media area.
Histopathology and immunohistochemistry
For immunohistochemistry, serial sections were blocked for endogenous peroxidase activity with 3% hydrogen peroxide in methanol following antigen retrieval in Antigen Unmasking Solution (Vector Laboratories) at 95°C. Sections were blocked with Protein Block (Dako) for 1 h and were incubated with anti-Mac3 (1:50; BD Biosciences) primary antibodies. Sections were incubated with a biotinylated secondary antibody and visualized by 3,3′-diaminobenidine and counterstained with hematoxylin. Sections were examined, and images of sections were collected using a Zeiss Axioskop microscope (Carl Zeiss) with a 20× or 40× CP-ACHROMAT/0.12NA objective. Images were acquired using a SPOT RT color camera (Diagnostic Instruments). To quantify the number of macrophages within the neointima of each experimental group, Mac-3+ cells and SMCs were counted in three random 40× images by a blinded observer. To correct for a reduction in cell volume within the neointima, a ratio of Mac-3+ cells and SMC was calculated and analyzed for each mouse.
Isolation of bone-marrow-derived macrophages and characterization
Bone-marrow-derived macrophage isolation and characterization was performed as described (13). Proliferation was assessed by incorporation of radioactive thymidine in WT and Nf1+/– BM-derived macrophages. Briefly, WT and Nf1+/– macrophages (5 × 104 cells) were serum-starved for 12–18 h and placed in a 96-well plate in 200 μl starvation media in either the absence or presence of MCP-1 (10 ng/ml). Cells were cultured for 24 h and subsequently pulsed with 1.0 μCi (0.037 MBq) [3H] thymidine for 6 h. Cells were harvested using a cell harvester and thymidine incorporation was determined as counts per minute (cpm).
For macrophage migration, the bottom of Transwell filters (8-μm pore filter; Costar) were coated with 20 μg/ml fibronectin CH296 peptide for 2 h at 37°C and rinsed twice with PBS containing 2% BSA. WT and Nf1+/– macrophages (2.5 × 105 cells) were placed in the upper chamber of the transwell and allowed to migrate toward the bottom of the transwell containing indicated concentration of MCP-1. After 24 h, non-migrated cells in the upper chamber were removed with a cotton swab and migrated cells that attached to the bottom surface of the membrane were stained with 0.1% crystal violet dissolved in 0.1 M borate, pH 9.0 and 2% ethanol for 5 min at room temperature. The number of migrated cells was determined in five random fields with an inverted microscope using a 20 × objective lens. All experiments were performed in triplicate.
Smooth muscle cell isolation and proliferation
SMC isolation and proliferation assays were performed as described (14). SMCs were obtained by outgrowth from explants of WT, Nf1+/− and Nf1+/−;CCR2−/− thoracic aortas. SMCs were cultured in DMEM supplemented with 10% fetal bovine serum and 100 U/ml penicillin/streptomycin in a 37°C, 5% CO2-humidified incubator. For cell proliferation, SMC (5000 cells/cm2) were placed in a 96-well plate and deprived of growth factors for 12–18 h. Quiescent SMC were stimulated with MCP-1 (10 ng/ml) for 24 h and pulse-labeled with 1 µCi/ml of [3H] thymidine for 6 h. Beta emission was measured and reported as cpm. In some experiments, SMCs were incubated with indicated concentrations of PD0325901 (Erk inhibitor). All experiments were performed in triplicate.
All values are presented as mean or percent ± SEM. Cell proliferation and migration were analyzed by two-way ANOVA with Tukey's post hoc test for multiple comparisons. All experiments were performed in triplicate. MCP-1 concentration was analyzed by Student's t-test. Intima area and I/M ratio analysis was assessed by one-way ANOVA with Tukey's post hoc test for multiple comparisons. Murine experiments utilizing INCB 3284 were analyzed using two-way ANOVA with Tukey's post hoc test for multiple comparisons. Percent Mac-3+ cells was analyzed by Student's t-test. Analysis was performed using GraphPad Prism version 5.0d. P < 0.05 were considered significant.
This work is supported by the Department of Defense (NF140031, B.K.S.), the American Heart Association (15SDG2550005, B.K.S.), the Department of Pediatrics at Augusta University (B.K.S.) and the National Institutes of Health (P50 NS052606, D.A.I.).
Conflict of Interest statement. None declared.